Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144338 · ClinicalTrials.gov registry record · Phase 3
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 14,752
- Enrollment target
NCT01144338 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 14,752 participants.
The verdict
NCT01144338, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14,752 participants
- Enrollment target
Study Summary
This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.
Interventions
- DRUG Placebo
- DRUG Exenatide Once Weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,752 participants |
| Start Date | 2010-06-18 |
| Est. Completion | 2017-04-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144338
The ClinicalTrials.gov registry entry for NCT01144338 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14,752 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01144338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144338 about?
NCT01144338 is a clinical study titled "Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus". This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.
What is the current status of trial NCT01144338?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14,752 participants. The study started on 2010-06-18. Estimated completion is 2017-04-24.
What interventions are being tested in trial NCT01144338?
The interventions under investigation include: Placebo (DRUG), Exenatide Once Weekly (DRUG).
Who is sponsoring clinical trial NCT01144338?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.